Analysts Issue Forecasts for VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a note issued to investors on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($0.98) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $5.73 target price on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.89) per share.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same period in the previous year, the business earned ($0.59) EPS.

VYGR has been the topic of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price objective for the company. StockNews.com lowered shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Wedbush began coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an "outperform" rating and a $11.00 price objective for the company. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of "Buy" and an average price target of $15.97.

Voyager Therapeutics Stock Down 4.4 %

VYGR stock traded down $0.23 during trading on Tuesday, hitting $5.05. The company had a trading volume of 445,551 shares, compared to its average volume of 406,706. The firm has a 50-day moving average price of $6.07 and a 200-day moving average price of $6.79. The stock has a market cap of $275.86 million, a price-to-earnings ratio of 7.11 and a beta of 0.93. Voyager Therapeutics has a 12 month low of $5.03 and a 12 month high of $10.66.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Armistice Capital LLC increased its position in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock worth $41,132,000 after buying an additional 528,000 shares during the period. Great Point Partners LLC acquired a new position in Voyager Therapeutics in the second quarter valued at about $12,668,000. Geode Capital Management LLC raised its position in shares of Voyager Therapeutics by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock valued at $6,316,000 after buying an additional 6,740 shares in the last quarter. Erste Asset Management GmbH bought a new position in Voyager Therapeutics in the third quarter valued at approximately $6,192,000. Finally, American Century Companies Inc. increased its stake in shares of Voyager Therapeutics by 32.4% in the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company's stock valued at $8,063,000 after purchasing an additional 249,659 shares during the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.